CC
AZN icon

Cannell & Co’s AstraZeneca AZN Stock Holding History

Cannell & Co’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,593
Closed -$4.09M – 260
2023
Q2 		$4.09M Sell
28,593
-22,455
-44% -$3.3M 0.14% 112
2023
Q1 		$7.09M Sell
51,048
-89,862
-64% -$12.1M 0.25% 95
2022
Q4 		$19.1M Buy
+140,910
New +$17.7M 0.69% 58
2022
Q3 		– Sell
-355,548
Closed -$47M – 264
2022
Q2 		$47M Buy
355,548
+11,163
+3% +$1.46M 1.69% 13
2022
Q1 		$45.7M Buy
344,385
+211,575
+159% +$25.4M 1.37% 17
2021
Q4 		$15.5M Buy
+132,810
New +$15.6M 0.44% 67

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Cannell & Co's AZN Position: Q3 2023 in Review

Cannell & Co sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 28,593 shares — an estimated $4.09M sold.

Cannell & Co first reported a position in AZN in Q4 2021 and held it in 6 quarters. The position peaked at $47M in Q2 2022. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

  • Cannell & Co reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
  • Cannell & Co sold 28,593 AstraZeneca shares in Q3 2023, an estimated $4.09M.
  • Cannell & Co first reported a position in AstraZeneca in Q4 2021 and held it in 6 quarters.
  • Cannell & Co's AstraZeneca position peaked at $47M in Q2 2022.
  • 1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Cannell & Co's 13F filing for Q3 2023, filed 14 Nov 2023.